13 citations
,
January 2013 in “International Journal of Trichology”
This study found that androgenetic alopecia patients showed significantly higher perifollicular lymphocytic inflammation and fibrosis compared to controls, emphasizing the need for histopathological evaluation during hair transplantation.
5 citations
,
June 2019 in “British Journal of Dermatology”
No results are provided in this article as it lacks an available abstract, making it unclear what effects apremilast and tofacitinib have in a humanized mouse model of alopecia areata.
This study found that patients with alopecia areata and androgenic alopecia had significantly increased mast cell infiltration, which was influenced by age and disease severity, especially in alopecia areata.
Aminexil/Kopexil may help reduce hair loss by addressing perifollicular fibrosis in androgenetic alopecia, but it lacks the extensive clinical backing of finasteride and minoxidil. Some users find it effective, but availability and cost are issues, especially in the US where it's not FDA-approved.
The user experienced significant hair loss after 9 months of using 0.5mg dutasteride and oral minoxidil, possibly due to alopecia areata. It is advised to consult a doctor for accurate diagnosis and treatment, as dutasteride and finasteride may not be effective.
The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.
A 19-year-old has been experiencing diffuse thinning since age 16 and has not seen improvement despite using minoxidil, finasteride, dutasteride, and other treatments. Suggestions include increasing dutasteride dosage, using RU58841, and considering topical treatments or a hair transplant.
Prolactin may contribute to hair loss, but targeting its receptor won't cure androgenetic alopecia. ABS-201 could be a useful alternative or adjuvant therapy, similar to JAK inhibitors, but not more effective than HMI-115.